N-(3-nitrophenyl)-2-phenylquinazolin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(3-nitrophenyl)-2-phenylquinazolin-4-amine
• 化学式: C₂₀H₁₄N₄O₂
• 分子量: 342.357
• InChiKey: KBEUKMLEXDGSBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(3-nitrophenyl)-2-phenylquinazolin-4-amine 、 碘甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以79%的产率得到N-methyl-N-(3-nitrophenyl)-2-phenylquinazolin-4-amine
  参考文献：
  名称：

  喹唑啉衍生物的合成和生物学评估-新型ABCG2抑制剂的SAR研究

  摘要：

  多药耐药性（MDR）是有效进行癌症化学疗法治疗的主要障碍，常常导致治疗失败。MDR通常与ABC转运蛋白（如ABCB1或ABCG2）的过表达有关，这些蛋白以ATP水解为代价将有害物质排出细胞。克服MDR的一种方法是使用有效的ABC转运蛋白抑制剂来恢复细胞对细胞生长抑制剂的敏感性。这项研究的重点是合成和评估新型2，4-二取代喹唑啉衍生物的结构-活性-关系（SAR），其逆转MDR的能力以及与ABCG2相互作用的方式。因此，确定了对ABCG2的抑制效力和选择性。此外，研究了内在的细胞毒性和MDR的逆转。进行了与底物Hoechst 33342的相互作用类型研究以及ABCG2与5D3单克隆抗体的构象分析，以更好地了解其潜在机制。在我们的研究中，我们可以进一步增强对ABCG2的抑制作用（化合物31，IC 50：55纳米），并确定的结构特征是对于抑制效力至关重要的，在转运活性的影响，并结合蛋白。

  DOI：

  10.1016/j.ejmech.2018.10.026
• 作为产物：
  描述：

  2-苯基-4-[3H]喹唑啉酮 在 三氯氧磷 作用下， 以 异丙醇 为溶剂， 反应 9.0h， 生成 N-(3-nitrophenyl)-2-phenylquinazolin-4-amine
  参考文献：
  名称：

  Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2)

  摘要：

  Chemotherapy is one of the major forms of cancer treatment. Unfortunately, tumors are prone to multidrug resistance leading to failure of treatment. Breast cancer resistance protein (BCRP), the second member of ABC transporter subfamily G, has been found to play a major role in drug efflux and hence multidrug resistance. Until now, very few potent and selective BCRP inhibitors like Ko143 have been identified. In the search for more potent and selective BCRP inhibitors, we synthesized and investigated a series of differently substituted quinazoline compounds. Several variations at positions 2, 4, 6 and 7 of the quinazoline scaffold were carried out to develop a structure-activity-relationship analysis for these compounds. It was found that compounds bearing a phenyl substituent at position 2 of the 4-anilinoquinazoline scaffold were most potent. On the aniline ring at position 4 of the quinazoline moiety substituents like NO2, CN, CF3 led to very high BCRP inhibition potencies. The most potent compounds were further investigated for their intrinsic cytotoxicity and their ability to reverse the multidrug resistance. Compound 20, an anilinoquinazoline bearing a phenyl ring at position 2 and meta-nitro substitution on the 4-anilino ring, was found to have the highest therapeutic ratio. The most active compounds from each variation were also investigated for their effect on BCRP expression. It was found that compound 20 has no significant effect on BCRP expression, while compound 31 decreased the surface BCRP expression. The only difference in the two compounds was the presence of a 3,4-dimethoxyphenyl ring in compound 31 instead of phenyl substitution at position 2 of the quinazoline moiety. From the study of all target compounds, compound 20 was the most prominent compound having inhibitory potency even higher than Ko143, the most potent BCRP inhibitor known. Compound 20 was also found to be selective towards BCRP with a very high therapeutic ratio. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.10.007

文献信息

• 4-Substituted-2-phenylquinazolines as inhibitors of BCRP
  作者：Kapil Juvale、Michael Wiese

  DOI：10.1016/j.bmcl.2012.08.024

  日期：2012.11

  We investigated several 2-phenylquinazolines with different substitutions at position 4 for their BCRP inhibition. Compounds with phenyl ring attached via an amine-containing linker at position 4 were found to be potent inhibitors of BCRP. In general compounds with meta substitution of phenyl ring at position 4 were found to have higher inhibitory effect, compound 12 being the most potent and selective towards BCRP. (C) 2012 Elsevier Ltd. All rights reserved.
• Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities
  作者：Sung J. Lee、Yoshitaka Konishi、Dingwei T. Yu、Tamara A. Miskowski、Christopher M. Riviello、Orest T. Macina、Manton R. Frierson、Kigen Kondo、Masafumi Sugitani

  DOI：10.1021/jm00018a014

  日期：1995.9

  Moderate cyclic GMP phosphodiesterase (cGMP-PDE, PDE V) inhibitor 2-phenyl-4-anilino-quinazoline (1) was identified utilizing MultiCASE assisted drug design (MCADD) technology. Modification of compound 1 was conducted at the 2-, 4-, and 6-positions of the quinazoline ring for enhancement of cGMP-PDE inhibitory activity. The 6-substituted 2-(imidazol-1-yl)-quinazolines are 1000 times more potent in in vitro PDE V enzyme assay than the well-known inhibitor zaprinast. The 6-substituted derivatives of 2-(3-pyridyl)quinazoline 84 and 2-(imidazol-1-yl)quinazoline 86 exhibited more than 1000-fold selectivity for PDE V over the other four PDE isozymes. In addition, cGMP-PDE inhibitors 64, 65, and 73 were found to have an additional property of thromboxane synthesis inhibitory activity.
• 10.22037/ijps.v19i1.43111
  作者：Seydbagian, Nasser、Dehghan-Ghahfarokhi, Esmaeil、Abdollahi, Soosan、Rezaeinasab, Rezvan

  DOI：10.22037/ijps.v19i1.43111

  日期：——
• Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2)
  作者：Kapil Juvale、Jennifer Gallus、Michael Wiese

  DOI：10.1016/j.bmc.2013.10.007

  日期：2013.12

  Chemotherapy is one of the major forms of cancer treatment. Unfortunately, tumors are prone to multidrug resistance leading to failure of treatment. Breast cancer resistance protein (BCRP), the second member of ABC transporter subfamily G, has been found to play a major role in drug efflux and hence multidrug resistance. Until now, very few potent and selective BCRP inhibitors like Ko143 have been identified. In the search for more potent and selective BCRP inhibitors, we synthesized and investigated a series of differently substituted quinazoline compounds. Several variations at positions 2, 4, 6 and 7 of the quinazoline scaffold were carried out to develop a structure-activity-relationship analysis for these compounds. It was found that compounds bearing a phenyl substituent at position 2 of the 4-anilinoquinazoline scaffold were most potent. On the aniline ring at position 4 of the quinazoline moiety substituents like NO2, CN, CF3 led to very high BCRP inhibition potencies. The most potent compounds were further investigated for their intrinsic cytotoxicity and their ability to reverse the multidrug resistance. Compound 20, an anilinoquinazoline bearing a phenyl ring at position 2 and meta-nitro substitution on the 4-anilino ring, was found to have the highest therapeutic ratio. The most active compounds from each variation were also investigated for their effect on BCRP expression. It was found that compound 20 has no significant effect on BCRP expression, while compound 31 decreased the surface BCRP expression. The only difference in the two compounds was the presence of a 3,4-dimethoxyphenyl ring in compound 31 instead of phenyl substitution at position 2 of the quinazoline moiety. From the study of all target compounds, compound 20 was the most prominent compound having inhibitory potency even higher than Ko143, the most potent BCRP inhibitor known. Compound 20 was also found to be selective towards BCRP with a very high therapeutic ratio. (C) 2013 Elsevier Ltd. All rights reserved.
• Synthesis and biological evaluation of quinazoline derivatives – A SAR study of novel inhibitors of ABCG2
  作者：Michael K. Krapf、Jennifer Gallus、Anna Spindler、Michael Wiese

  DOI：10.1016/j.ejmech.2018.10.026

  日期：2019.1

  One way to overcome MDR is to apply potent inhibitors of ABC transporters to restore the sensitivity of the cells toward cytostatic agents. This study focusses on the synthesis and evaluation of novel 2,4-disubstituted quinazoline derivatives regarding the structure-activity-relationship (SAR), their ability to reverse MDR and their mode of interaction with ABCG2. Hence, the inhibitory potency and

  多药耐药性（MDR）是有效进行癌症化学疗法治疗的主要障碍，常常导致治疗失败。MDR通常与ABC转运蛋白（如ABCB1或ABCG2）的过表达有关，这些蛋白以ATP水解为代价将有害物质排出细胞。克服MDR的一种方法是使用有效的ABC转运蛋白抑制剂来恢复细胞对细胞生长抑制剂的敏感性。这项研究的重点是合成和评估新型2，4-二取代喹唑啉衍生物的结构-活性-关系（SAR），其逆转MDR的能力以及与ABCG2相互作用的方式。因此，确定了对ABCG2的抑制效力和选择性。此外，研究了内在的细胞毒性和MDR的逆转。进行了与底物Hoechst 33342的相互作用类型研究以及ABCG2与5D3单克隆抗体的构象分析，以更好地了解其潜在机制。在我们的研究中，我们可以进一步增强对ABCG2的抑制作用（化合物31，IC 50：55纳米），并确定的结构特征是对于抑制效力至关重要的，在转运活性的影响，并结合蛋白。